2 March 2026 in Nature Structural & Molecular Biology
5 March 2026 in Nature Communications
Pathogenic variants in NLRP7, implicated in 55% of recurrent hydatidiform mole characterized by hypomethylation at maternally methylated imprinted regions, are proposed to disrupt de novo DNA methylation in human oocytes. However, the precise mechanism remains unclear. Here, we identify TCL1A, a DNMT3A inhibitor, as an endogenous NLRP7-interacting partner. The cryo-EM structure of the NLRP7-TCL1A complex reveals its fundamental architecture. Comprehensive analysis demonstrates that the majority of recurrent hydatidiform mole-causing NLRP7 variants impair its interaction with TCL1A. Mechanistically, NLRP7 potentially safeguards oocyte methylome by sequestering TCL1A in the cytoplasm, thereby preventing its nuclear entry and subsequent suppression of DNMT3A-mediated de novo methylation. Combining in silico predictions and interaction analysis, we identify L766R as a pathogenic variant. These findings propose a cytoplasmic regulatory mechanism governing nuclear DNA methylation, explaining the hypomethylation pathogenesis in NLRP7 variant-associated recurrent hydatidiform mole.
8 April 2026 in Nature Communications
NLRP14 is an essential maternal factor for mammalian embryonic development. Maternal ablation of NLRP14 in mice impairs DNA demethylation and calcium homeostasis in zygotes, causing early embryonic arrest. However, the underlying biochemical events remain largely unknown. Here, we identified two binding partners (KDM2A and UHRF1) of NLRP14 and further solved structures of NLRP14-KDM2A-SKP1 and NLRP14-UHRF1. Structural analysis revealed that NLRP14 modulates the SKP1-CUL1-F-box (SCF) E3 ubiquitin ligase and the RING-type E3 ubiquitin ligase UHRF1 through two distinct mechanisms. Mechanistically, NLRP14 competitively inhibits KDM2A-mediated SCF assembly or allosterically inhibits the activity of UHRF1 by occupying the E2 ubiquitin-conjugating enzyme (UBE2D) binding site of the ubiquitin-like (UBL) domain. Deletion of NLRP14 in mice increases ubiquitination levels in oocytes during maturation and after fertilization. Collectively, our findings identify NLRP14 as a dual regulator that restrains E3 ubiquitin ligase-driven ubiquitination by limiting SCF complex assembly and attenuating UHRF1 activity. This regulatory role is required to prevent excessive protein ubiquitination and maintain proteostasis during the oocyte-to-embryo transition, thereby supporting early embryonic development. Our study uncovers maternal regulation of proteostasis in oocytes and suggests that dysregulating proteostasis is an important factor in the pathogenesis of reproductive disorders.
17 October 2026 in Nature Communications
Peptidyl arginine deiminase 6 (PADI6) is an essential maternal effector in mammalian oocytes and preimplantation embryos. Recently, we identified the conserved maternal PADI6-UHRF1-UBE2D complex (MPU). MPU, together with the subcortical maternal complex (SCMC), further forms the cytoplasmic lattices (CPLs). Here, we reconstitute the mouse MPU (mMPU) and uncover striking species-specific differences in PADI6 oligomerization. In solution, mouse PADI6 (mPADI6) undergoes further oligomerization, forming tetramers, higher-order oligomers, and filamentous assemblies. Cryo-EM analysis reveals that the N-terminal IgG domain of mPADI6 mediates this behavior. These distinct oligomerization properties alter the stoichiometric ratios of the three components during assembly of both human MPU and mMPU. Moreover, PADI6 from different species adopts distinct oligomeric states in solution, suggesting potential differences in CPL assembly mechanisms. Together, our findings define the differential oligomerization capacity of PADI6 at the molecular level and provide a critical framework for understanding PADI6-mediated maternal regulatory assemblies during early embryonic development in different species.